Skip to main content
SpringerLink
Log in

Neue Aspekte in der Therapie der neovaskulären altersabhängigen Makuladegeneration

Aktuelle Stellungnahme der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft und des Berufsverbands der Augenärzte Deutschlands e.V. (Stand: März 2009)

  • Medizin aktuell
  • Published:
Der Ophthalmologe Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. http://www.controlled-trials.com/ISRCTN92166560

  2. http://www.pharmakologie-bremen.de/index.php/klinische-forschung/vibera

  3. http://www.clinicaltrials.gov/ct2/show/NCT00559715

  4. http://www.med.upenn.edu/cpob/studies/CATT.shtml

  5. Stellungnahme zu aktuellen therapeutischen Möglichkeiten bei der neovaskulären altersabhängigen Makuladegeneration (2006) Klin Monatsbl Augenheilkd 223:271–278

    Google Scholar 

  6. http://www.dog.org/publikationen/DOG_Empfehlung_Intravitreale_Injektionen.pdf

  7. Aktuelle therapeutische Möglichkeiten bei der neovaskulären altersabhängigen Makuladegeneration. Stellungnahme der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft und des Berufsverbands der Augenärzte Deutschlands zu aktuellen therapeutischen Möglichkeiten bei der neovaskulären altersabhängigen Makuladegeneration (2007) Ophthalmologe 104:628–634

  8. Stellungnahme der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft und des Berufsverbands der Augenärzte Deutschlands zu aktuellen therapeutischen Moglichkeiten bei der neovaskulären altersabhängigen Makuladegeneration (2007) Klin Monatsbl Augenheilkd 224:559–566

  9. http://library.corporate-ir.net/library/11/119/119576/items/309061/Final2_0508_Week52_Website_Slides_9-26-08.pdf

  10. OPKO Health announces completion of enrollment for Its phase III clinical trial of bevasiranib for treatment of AMD (2008) investor.opko.com/releasedetail.cfm?ReleaseID=352313

  11. http://www.nice.org.uk/TA155

  12. Aiello LP, Brucker AJ, Chang S et al (2004) Evolving guidelines for intravitreous injections. Retina 24:S3–S19

    Article  PubMed  Google Scholar 

  13. Alexander SL, Linde-Zwirble WT, Werther W et al (2007) Annual rates of arterial thromboembolic events in medicare neovascular age-related macular degeneration patients. Ophthalmology 114:2174–2178

    Article  PubMed  Google Scholar 

  14. Angulo Bocco MC, Glacet-Bernard A, Zourdani A et al (2008) Injection intravitréenne: Évaluation rétrospective de la technique et des complications d’une serie de 2028 injections. J Fr Ophtalmol 31:693–698

    Article  Google Scholar 

  15. Antoszyk AN, Tuomi L, Chung CY et al (2008) Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol 145:862–874

    Article  PubMed  CAS  Google Scholar 

  16. Brown DM, Kaiser PK, Michels M et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432–1444

    Article  PubMed  CAS  Google Scholar 

  17. Chakravarthy U, Adamis AP, Cunningham ET Jr et al (2006) Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 113:1508–1521

    PubMed  Google Scholar 

  18. Chappelow AV, Kaiser PK (2008) Neovascular age-related macular degeneration: Potential therapies. Drugs 68:1029–1036

    Article  PubMed  CAS  Google Scholar 

  19. Colquitt JL, Jones J, Tan SC et al (2008) Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: A systematic review and economic evaluation. Health Technol Assess 12:iii–iv, ix–201

    PubMed  CAS  Google Scholar 

  20. Dafer RM, Schneck M, Friberg TR et al (2007) Intravitreal ranibizumab and bevacizumab: A review of risk. Semin Ophthalmol 22:201–204

    Article  PubMed  Google Scholar 

  21. Dejneka NS, Wan S, Bond OS et al (2008) Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes. Mol Vis 14:997–1005

    PubMed  CAS  Google Scholar 

  22. Dierks C, Nitz G (2008) Rechtsfortbildung dank Lucentis? Gesellschaftspolitische Kommentare 11:3–7

    Google Scholar 

  23. Farah SE (2008) Treatment of neovascular age-related macular degeneration with pegaptanib and boosting with bevacizumab or ranibizumab as needed. Ophthalmic Surg Lasers Imaging 39:294–298

    Article  PubMed  Google Scholar 

  24. Fintak DR, Shah GK, Blinder KJ et al (2008) Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina 28:1395–1399

    Article  PubMed  Google Scholar 

  25. Francke R, Hart D (2003) Off label use - Arzneimittelrechtliche, haftungsrechtliche, berufsrechtliche und sozialrechtliche Fragen. Die Sozialgerichtsbarkeit 50:653–664

    Google Scholar 

  26. Gamulescu MA, Framme C, Sachs H (2007) RPE-rip after intravitreal bevacizumab (Avastin) treatment for vascularised PED secondary to AMD. Graefes Arch Clin Exp Ophthalmol 245:1037–1040

    Article  PubMed  CAS  Google Scholar 

  27. Gragoudas ES, Adamis AP, Cunningham ET Jr et al (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351:2805–2816

    Article  PubMed  CAS  Google Scholar 

  28. Hart D (2008) Arzthaftung und off label use. Information, Standard und Zulassung. In: Medizinrecht DAA (Hrsg) Medizinrecht heute: Erfahrungen, Analysen, Entwicklungen. Festschrift: 10 Jahre Arbeitsgemeinschaft Medizinrecht im DAW: Deutscher Anwaltverlag 173–190

  29. Hart D (2008) Off-Label-Use von Arzneimitteln: Hintergründe und Lösungsansätze eines vielschichtigen Problems. Arzneimittelbrief 42:81–96

    Google Scholar 

  30. Heimes B, Lommatzsch A, Zeimer M et al (2008) Foveal RPE autofluorescence as a prognostic factor for anti-VEGF therapy in exudative AMD. Graefes Arch Clin Exp Ophthalmol 246:1229–1234

    Article  PubMed  CAS  Google Scholar 

  31. Hughes MS, Sang DN (2006) Safety and efficacy of intravitreal bevacizumab followed by pegaptanib maintenance as a treatment regimen for age-related macular degeneration. Ophthalmic Surg Lasers Imaging 37:446–454

    PubMed  Google Scholar 

  32. Ip MS, Scott IU, Brown GC et al (2008) Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: A report by the American Academy of Ophthalmology. Ophthalmology 115:1837–1846

    Article  PubMed  Google Scholar 

  33. Kleinman ME, Yamada K, Takeda A et al (2008) Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452:591–597

    Article  PubMed  CAS  Google Scholar 

  34. Kook D, Wolf A, Neubauer AS et al (2008) Retinale Pigmentepithelrisse nach intravitrealem Bevacizumab bei AMD. Häufigkeit und Verlauf. Ophthalmologe 105:158–164

    Article  PubMed  CAS  Google Scholar 

  35. Lommatzsch AP, Heimes B, Gutfleisch M et al (2008) Die Therapie der vaskularisierten serosen Pigmentepithelabhebung bei AMD - Beobachtungen nach Wechsel des intravitrealen Medikamentes bei Therapieversagen. Klin Monatsbl Augenheilkd 874–879

  36. Macular Photocoagulation Study Group (1991) Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch Ophthalmol 109:1109–1114

    Google Scholar 

  37. Meyer CH, Mennel S, Eter N (2007) Endophthalmitisrate mit und ohne topische postoperative Antibiotikagabe nach intravitrealer Avastin-injektion. Ophthalmologe 104:952–957

    Article  PubMed  CAS  Google Scholar 

  38. Nguyen QD, Shah SM, Hafiz G et al (2006) A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 113:1522 e1521–1522 e1514

    Article  PubMed  Google Scholar 

  39. Novartis NSO, Basel CH (2008) Investigator Notification for ranibizumab: Lucentis Meta-Analysis

  40. Novartis Pharma GmbH (2008) Fachinformation Lucentis® (Stand August 2008). Rote Liste GmbH

  41. Regillo CD, Brown DM, Abraham P et al (2008) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 145:239–248

    Article  PubMed  CAS  Google Scholar 

  42. http://www.pei.de/SharedDocs/Downloads/fachkreise/rhb/09-02-11-rhb-avastin,templateId=raw,property=publicationFile.pdf/09-02-11-rhb-avastin.pdf

  43. Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431

    Article  PubMed  CAS  Google Scholar 

  44. Schmidt-Erfurth U, Wolf S (2008) Same-day administration of verteporfin and ranibizumab 0.5 mg in patients with choroidal neovascularisation due to age-related macular degeneration. Br J Ophthalmol 92:1628–1635

    Article  PubMed  CAS  Google Scholar 

  45. Schmidt-Erfurth UM, Richard G, Augustin A et al (2007) Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmol Scand 85:486–494

    Article  PubMed  CAS  Google Scholar 

  46. Schouten JS, La Heij EC, Webers CA et al (2009) A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 247:1–11

    Article  PubMed  CAS  Google Scholar 

  47. Scott IU, Flynn HW Jr (2007) Reducing the risk of endophthalmitis following intravitreal injections. Retina 27:10–12

    Article  PubMed  Google Scholar 

  48. Singerman LJ, Masonson H, Patel M et al (2008) Pegaptanib sodium for neovascular age-related macular degeneration: Third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br J Ophthalmol 92:1606–1611

    Article  PubMed  CAS  Google Scholar 

  49. Weinberger AW, Thiel M, Mohammadi B et al (2007) Retinal pigment epithelium tears after intravitreal bevacizumab in pigment epithelium detachment. Am J Ophthalmol 144:294–296

    Article  PubMed  CAS  Google Scholar 

  50. http://www.eprints.hta.lbg.ac.at/718/1/Rapid_Assessment_002.pdf

  51. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H et al (2008) Twelve-month safety of intravitreal injections of bevacizumab (Avastin(R)): Results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 246:81–87

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Neue Aspekte in der Therapie der neovaskulären altersabhängigen Makuladegeneration. Ophthalmologe 106, 457–464 (2009). https://doi.org/10.1007/s00347-009-1969-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00347-009-1969-2

Search

Navigation